COVID-19 Infusion Information for Providers
Updated January 18, 2021
Check back often for updates to this page.
Urgent Monoclonal Antibody Update
Beginning Monday, December 21: If a patient arrives for a monoclonal antibody treatment and confirmed SPO2 is <94, he or she will be referred back to the referring provider without receiving infusion. 94% saturation is the cut off for differentiating between moderate and severe in the NIH Guidelines for severity of disease in COVID-19.
Given the current utilization of monoclonal antibodies and limited allocations received from the state it is anticipated that demand will exceed our supply the week of December 20-26. Drugs will be administered to patients who meet criteria according to when the orders are received. Please note that a referral order does not guarantee doses will be available to administer. Patient still within the inclusion criteria for symptom onset will be scheduled if doses do become available.
This information is for health care providers who are interested in referring a COVID-19 patient for bamlanivimab or casirivimab/imdevimab (monoclonal antibody treatment).
The FDA has issued an Emergency Use Authorization (EUA) for bamlanivimab and casirivimab/imdevimab for treatment of mild to moderate COVID-19.
High risk is defined as patients who meet at least one of the following criteria:
- Body mass index (BMI) 35 or above
- Chronic Kidney Disease
- Immunosuppressive disease or on immunosuppressive medication
- Age 65 or older
- Age 55 or older AND have
- Cardiovascular disease, OR
- Hypertension, OR
- Chronic obstructive pulmonary disease/other chronic respiratory disease
- Do not meet inclusion criteria
- Require oxygen due to COVID-19 or require an increase in oxygen from baseline
- History of allergic reaction to monoclonal antibody administration
- Confirmed SPO2 at time of treatment is <94 (except in cases where provider confirms known baseline pulse ox of less than 94% and does not meet criteria for home oxygen.)
Note: Any questions about the medication, side effects, referral criteria, etc., will be directed to the provider. The office phone number is for referral scheduling only.
These treatments are currently being given in three locations:
- 612 Brunson Drive, Tupelo
- NMMC-Iuka, 1777 Curtis Drive, Iuka
- NMMC Gilmore-Amory, 1105 Earl Frye Blvd., Amory
- NMMC-West Point, 977 Emergency Dr., West Point
Referral Information (EPIC)
Providers with EPIC access: Your referrals must be made in EPIC, and a therapy plan is also required.
EPIC referral tip sheet
SCM referral tip sheet
Referral Form to Fax (Tupelo)
Referral Form to Fax (Iuka)
Referral Form to Fax (Amory)
Referral Form to Fax (West Point)
Referral phone numbers
Tupelo: (662) 377-2430
Iuka: (662) 423-4060
Amory: (662) 256-6061
West Point: (662)
Resources for Providers
Criteria and important info to print (Tupelo)
Criteria and important info to print (Amory)
Criteria and important info to print (Iuka)
Criteria and important info to print (West Point)
Bamlanivimab FDA Fact Sheet for Providers
Casirivimab/Imdevimab FDA Fact Sheet for Providers
Resources for Patients
Info sheet to print and give to patients (Tupelo)
Info sheet to print and give patients (Amory)
Info sheet to print and give patients (Iuka)
Info sheet to print and give patients (West Point)
Bamlanivimab FDA Fact Sheet for Patients
Casirivimab/Imdevimab FDA Fact Sheet for Patients